The global healthcare private equity (PE) landscape is undergoing a structural realignment driven by macroeconomic pressures, valuation inflation in North American markets, and a flight toward cash-generative, operationally resilient assets. Global healthcare dealmaking reached $546.7 billion. However, aggregate capital deployment figures mask a stark divergence between market tiers. In North America and the global mega-cap buyout space, intense competition among bulge-bracke